{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:16:56Z","timestamp":1790144216979,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1038\/s41571-019-0183-7","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T11:19:52Z","timestamp":1551266392000},"page":"279-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anti-CD19 CAR T cell therapy for lymphoma \u2014 off to the races!"],"prefix":"10.1038","volume":"16","author":[{"given":"David G.","family":"Maloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"183_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"183_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45\u201356 (2019).","journal-title":"N. Engl. J. Med."},{"key":"183_CR3","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"183_CR4","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).","journal-title":"Sci. Signal."},{"key":"183_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"183_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"183_CR7","doi-asserted-by":"crossref","unstructured":"Schuster, S. J. et al. Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B cell lymphoma (r\/rDLBCL) treated with tisagenlecleucel on the JULIET study [abstract 4190]. Presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA (2018).","DOI":"10.1182\/blood-2018-99-113052"},{"issue":"Suppl. 15","key":"183_CR8","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2018.36.15_suppl.3003","volume":"36","author":"FL Locke","year":"2018","unstructured":"Locke, F. L. et al. Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-cel) in patients (Pts) with refractory large B cell lymphoma. J. Clin. Oncol. 36 (Suppl. 15), 3003 (2018).","journal-title":"J. Clin. Oncol."},{"key":"183_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","author":"DW Lee","year":"2018","unstructured":"Lee, D. W. et al. ASBMT consensus grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. \n                    https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758\n                    \n                   (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"183_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2018-08-868117","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil, L. J. et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T cell therapy for relapsed\/refractory large B cell lymphoma: real world experience. Blood 132, 91 (2018).","journal-title":"Blood"},{"issue":"Suppl. 15","key":"183_CR11","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","volume":"36","author":"J Abramson","year":"2018","unstructured":"Abramson, J. et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL. J. Clin. Oncol. 36 (Suppl. 15), 7505 (2018).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0183-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0183-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-019-0183-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:27:56Z","timestamp":1684621676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-019-0183-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["183"],"URL":"https:\/\/doi.org\/10.1038\/s41571-019-0183-7","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]},"assertion":[{"value":"27 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.M. has participated in and received honoraria for clinical advisory boards for Juno\/Celgene, Kite\/Gilead and Novartis. The employing institution of D.G.M. receives clinical trial research support from Juno\/Celgene and Kite\/Gilead.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}